Dr. Jim Tananbaum is the founding CEO of the Foresite Capital. This is a healthcare venture and a dedicated private equity firm that specializes in identifying emerging healthcare leaders and helping to boost their profitability by supplying information, advice, capital, and networks. The firm has more than 1.1 billion dollars in assets under management. The idea of starting Foresite Capital came in 2011. Jim had more than 25 years of experience as an entrepreneur and investments strategist in the healthcare industry. His focus is on strategic, operational, and financial opportunities to build franchise healthcare investments. Foresite Capital has invested in more than 77 different healthcare companies in Biopharmaceuticals, medical services & devices, diagnostics, and genomic sequencing. More details can be found on Crunchbase.
Dr. Jim Tananbaum holds a Master’s degree in Business Administration and M.D Degree from the Harvard Business School. He also holds a Master’s of Science from Massachusetts Institute of Technology. He has vast experience in the healthcare sector through investing and building healthcare companies. Jim is a former senior director at Illumina. He led investments in 21 successful healthcare companies including Amira Pharmaceuticals, Amerigroup group, and Jazz Pharmaceuticals. He previously founded and was the CEO of Thieravance, Inc. (NASDAQ: THRX). Jim founded GelTex Pharmaceuticals (NASDAQ: GENZ) after finishing Harvard Medical School. It was able to bring two drugs to the market for less than 80 million dollars. The drugs generate 1 billion dollars in revenues today. Thieravance and Biopharma, Inc. have a combined market cap of 2.75 billion dollars. It was later acquired at 1.6 billion dollars by Genzyme and Thieravance.
Dr. Jim Tananbaum was a founding partner of Prospect Venture Partners II and III. He was also a partner at Sierra Ventures where he was involved in helping to establish their healthcare services investment practice. Dr. Tananbaum has served on advisory boards and visiting committees to the Harvard-MIT HST program and Yale’s President Advisory Council. He is named among the top 100 best venture investors by Forbes Midas list for the third consecutive year due to several major healthcare investments. The Midas List recognizes the top 100 venture capitalists who lead in tech enterprises of the future and who create exceptional value for their investors.